To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Impact of high on-treatme… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Impact of high on-treatment platelet reactivity on outcomes following PCI in patients on hemodialysis: An ADAPT-DES substudy.

Journal article
Authors Rubin GA
Kirtane AJ
Chen S
Björn Redfors
Weisz G
Baber U
Zhang Y
Stuckey TD
Witzenbichler B
Rinalde MJ
Neumann FJ
Metzger DC
Henry DC
Cox DA
Duffy PL
Brodie BR
Mazzaferri EL
Mehran R
Ali ZA
Ben-Yehuda O
Stone GW
Published in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN 1522-726X
Publication year 2019
Published at Institute of Medicine, Department of Molecular and Clinical Medicine
Language en
Subject categories Cardiovascular medicine


We sought to compare clinical outcomes after percutaneous coronary intervention (PCI) in patients on versus not on hemodialysis (HD) and examine whether high on-treatment platelet reactivity (HPR) further impacts outcomes among patients on HD.Both chronic kidney disease (CKD) and HPR are predictors of major adverse cardiac events (MACE) after PCI.Two-year outcomes of patients from the prospective, multicenter ADAPT-DES study (N = 8,582) were analyzed according to HD status at enrollment. All patients underwent platelet function testing with the VerifyNow assay; HPR on clopidogrel was defined as P2Y12 reaction units (PRU) >208.Compared with non-HD patients, patients on HD (n = 85) had significantly higher baseline PRU (median 254 vs. 188, p = .001) and more frequently had HPR (61.7% vs. 42.5%, p < .001). HD was associated with increased 2-year rates of MACE (death, myocardial infarction (MI) or definite stent thrombosis (ST); 23.4% vs. 10.7%, p < .001). HD was also strongly associated with 2-year overall mortality, cardiac death, MI, target vessel revascularization, major bleeding, stroke and ST. Following adjustment for HPR and other covariates, HD was independently associated with overall mortality, MI, ST, and major bleeding at 2 years. The relationship between HD status and 2-year MACE was consistent in patients with and without HPR (Pinteraction = .78).Nearly two-thirds of patients on HD exhibited HPR on clopidogrel, and both HD and HPR were independently associated with 2-year adverse outcomes after DES implantation. However, the deleterious impact of HD on clinical outcomes was present in both patients with and without HPR.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?